Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 2/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.49 |
| ▸ | CSF1R | P07333 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | FDPS | P14324 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.42 |
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | CCR8 | P51685 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29580736 | 0.83 | CTSA (0.48) | CTSACSF1RFLT3FDPSGRM5 | |
| SCHEMBL171083 | 0.83 | CTSA (0.48) | CTSACSF1RFLT3FDPSGRM5 | |
| SCHEMBL10274536 | 0.82 | KMT2A (0.50) | CTSACSF1RFLT3MEN1KMT2A | |
| SCHEMBL168844 | 0.82 | MAOB (0.51) | CTSAFLT3MEN1KMT2AKDM4E | |
| SCHEMBL7083262 | 0.82 | CTSA (0.45) | CTSAMEN1KMT2AKDM4ENPC1 | |
| SCHEMBL13852609 | 0.81 | KMT2A (0.52) | CTSAMEN1KMT2AGRM5SMN1; SMN2 | |
| SCHEMBL171037 | 0.80 | EGLN1 (0.55) | CTSAMEN1KMT2AMMP13 | |
| SCHEMBL7171815 | 0.79 | KDM4E (0.57) | P2RX7KDM4E | |
| SCHEMBL15908508 | 0.79 | KMT2A (0.45) | CTSAMEN1KMT2AKDM4ENOS3 | |
| SCHEMBL31345733 | 0.79 | P2RX7 (0.50) | P2RX7KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3300500-B9 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-3300500-B9 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-3300500-B1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2020-02-26 | — | — | EP | disclosed |
| EP-3300500-B1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2020-02-26 | — | — | EP | disclosed |
| EP-3309161-B1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING A P2X7 MODULATOR | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-18 | — | — | EP | disclosed |
| EP-3309161-B1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING A P2X7 MODULATOR | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-18 | — | — | EP | disclosed |
| US-10344016-B2 | Bromotriazole intermediates | AMGEN INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-10344016-B2 | Bromotriazole intermediates | AMGEN INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20190100510-A1 | BROMOTRIAZOLE INTERMEDIATES | AMGEN INC. (US) | 2019-04-04 | — | — | US | disclosed |
| US-20190100510-A1 | BROMOTRIAZOLE INTERMEDIATES | AMGEN INC. (US) | 2019-04-04 | — | — | US | disclosed |
| WO-2014152537-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014152621-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014152621-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-25 | — | — | WO | disclosed |
| US-8501946-B2 | 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine derivatives as P2X7 modulators | GLAXO GROUP LIMITED (GB) | 2013-08-06 | — | — | US | disclosed |
| US-8501946-B2 | 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine derivatives as P2X7 modulators | GLAXO GROUP LIMITED (GB) | 2013-08-06 | — | — | US | disclosed |
| US-20120157436-A1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2012-06-21 | — | — | US | disclosed |
| US-20120157436-A1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2012-06-21 | — | — | US | disclosed |
| EP-2424869-A1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | Glaxo Group Limited (GB) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010125102-A1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010125102-A1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190100510-A1 | BROMOTRIAZOLE INTERMEDIATES | APH1A, BRDT, APH1B | CTSA 3011/4885P2RX7 3078/4885CSF1R 165/4885 |
| US-10344016-B2 | Bromotriazole intermediates | APH1A, BRDT, APH1B | CTSA 3011/4885P2RX7 3078/4885CSF1R 165/4885 |
| US-20120157436-A1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | P2RX7, P2RX6, P2RX3 | CTSA 2057/4885P2RX7 1/4885CSF1R 1467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.